Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study
Julie Valentin(Centre Hospitalier Universitaire de Bordeaux), E. Gérard(Université de Bordeaux), Thomas Ferté(Centre Hospitalier Universitaire de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), V. Dorizy‐Vuong(Hôpital Saint-André), Anne Pham‐Ledard(Peter MacCallum Cancer Centre), M. Beylot‐Barry, L. Dousset(Centre Hospitalier Universitaire de Bordeaux), S. Prey(Centre Hospitalier Universitaire de Bordeaux)
Cited by 21
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k